Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Summary

A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.

Timeline

Start

2020-03-01

Primary completion

2021-10-31

Completion

2022-04-30

Publications

• Azim HA, Saleh MA, Essam Eldin P, Abdelhafeez AAM, Hassan M, Kassem L. Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial. J Chemother. 2025 Apr;37(2):159-167. doi: 10.1080/1120009X.2024.2342741. Epub 2024 May 20.

Drugs

Indications